Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04637321
Other study ID # 059.PHA.2019.D
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 4, 2019
Est. completion date August 7, 2020

Study information

Verified date February 2022
Source Methodist Health System
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

2.1. Study Objectives - Primary Objective(s) - Identify the incidence and risk of CDI within one year after kidney, liver, and/or pancreas transplant - Secondary Objective(s) - Identify the risk factors for recurrent CDI post-transplant in patients who were diagnosed with a CDI within one year prior to Solid Organ Transplant - Evaluate the impact of CDI on graft survival following Solid Organ Transplant


Description:

- Single center, retrospective cohort chart review study design - Data will be collected on all liver, kidney, pancreas and combined transplant recipients who received their graft(s) from April 1, 2015 to July 31, 2018 - Will analyze outcomes from April 1, 2014 to July 31, 2019 - Patient list will be generated in Epic and Meditech - All data will be obtained from Epic and Meditech - All data will be collected retrospectively after the patient is discharged from the hospital


Recruitment information / eligibility

Status Completed
Enrollment 585
Est. completion date August 7, 2020
Est. primary completion date August 7, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Solid organ transplant patients who received graft(s) at MDMC from April 1, 2015 to July 31, 2018 - Age >18 years old Exclusion Criteria: - Age <18 years old - Loss to early death defined as within one week from transplantation - Patients whose primary address is in Puerto Rico

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Solid organ transplant
Data will be collected on all liver, kidney, pancreas and combined transplant recipients who received their graft(s) from April 1, 2015 to July 31, 2018

Locations

Country Name City State
United States Jessica Rago Dallas Texas

Sponsors (1)

Lead Sponsor Collaborator
Methodist Health System

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of C. Difficile infection (CDI) within one year post-transplant Incidence of C. Difficile infection within one year post-transplant for CDI post-transplant. April 1, 2014 to July 31, 2019
Primary Risk factors for CDI post-transplant - No.1 Risk factors transplanted organ April 1, 2014 to July 31, 2019
Primary Risk factors for CDI post-transplant - No.2 Origin of transplanted graft including age of donor April 1, 2014 to July 31, 2019
Primary Risk factors for CDI post-transplant No.-3 Induction agent used April 1, 2014 to July 31, 2019
Primary Risk factors for CDI post-transplant No.4 Acid suppression April 1, 2014 to July 31, 2019
Primary Risk factors for CDI post-transplant No.5 First time SOT recipient April 1, 2014 to July 31, 2019
Primary Risk factors for CDI post-transplant No.6 History of CDI in the year prior to transplant April 1, 2014 to July 31, 2019
Primary Risk factors for CDI post-transplant No.7 Co-infection with HIV/AIDS April 1, 2014 to July 31, 2019
Primary Risk factors for CDI post-transplant No.8 Length of hospital stay April 1, 2014 to July 31, 2019
Primary Risk factors for CDI post-transplant No. 9 Length of intensive care unit stay April 1, 2014 to July 31, 2019
Primary Risk factors for CDI post-transplant No.10 Intra-operative administration of blood products April 1, 2014 to July 31, 2019
Primary Risk factors for CDI post-transplant No. 11 Antibiotic use in the 90 days prior to infection April 1, 2014 to July 31, 2019
Primary Risk factors for CDI post-transplant No. 12 Antibiotic use in the 90 days post-transplant April 1, 2014 to July 31, 2019
Primary Risk factors for CDI post-transplant No, 13 Hospitalization in the 90 days prior to transplantation April 1, 2014 to July 31, 2019
Primary Risk factors for CDI post-transplant No, 14 Hospitalization in the 90 days post-transplant April 1, 2014 to July 31, 2019
See also
  Status Clinical Trial Phase
Completed NCT02260596 - Respiratory Viral Infections in Pediatric Transplantation N/A
Completed NCT01761435 - Clinical Trial Evaluating Efficacy and Safety of One Dose Versus Two Doses of Influenza Vaccination Phase 3
Completed NCT02382211 - T-SPOT.CMV and T-SPOT.PRT Diagnostic Assays
Terminated NCT01761201 - "Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients". Phase 3
Recruiting NCT05626530 - Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients Phase 4
Active, not recruiting NCT01527591 - Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT) N/A
Recruiting NCT02503982 - Valganciclovir Dosing in Pediatric Solid Organ Transplant Recipients Phase 4
Completed NCT01446445 - Individualization of Ganciclovir and Valganciclovir Doses Using Bayesian Prediction in Renal Transplant Patients. Phase 4
Completed NCT01833416 - Natural History of Cytomegalovirus (CMV) Infection and Disease Among Renal Transplant Recipients N/A
Completed NCT01558037 - Cell Mediated Immunity With Risk of Cytomegalovirus (CMV) in Solid Organ Transplant Recipients N/A